Outpatient Infusion

Krystexxa


KRYSTEXXA (also known as Pegloticase)

Mechanism:

Krystexxa is an enzyme that breaks down uric acid, which otherwise accumulates in gout and precipitates, causing gout flares.

Indications:

  • Gout who have not responded to conventional therapy.

Contraindications:

Patients with G6PD deficiency should not be started on Krystexxa.  Patients with heart failure should consult their physicians before starting on Krystexxa.

Administration:

Krystexxa is typically administered as an infusion every 2 weeks.

Copyright by Thrivewell 2017. All rights reserved.